JP2015520170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520170A5 JP2015520170A5 JP2015514227A JP2015514227A JP2015520170A5 JP 2015520170 A5 JP2015520170 A5 JP 2015520170A5 JP 2015514227 A JP2015514227 A JP 2015514227A JP 2015514227 A JP2015514227 A JP 2015514227A JP 2015520170 A5 JP2015520170 A5 JP 2015520170A5
- Authority
- JP
- Japan
- Prior art keywords
- metabolic syndrome
- hsp90
- hsp90 modulator
- modulator according
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710113864 Heat shock protein 90 Proteins 0.000 claims 40
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 40
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 40
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 18
- 238000000034 method Methods 0.000 claims 11
- 235000012000 cholesterol Nutrition 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 239000000523 sample Substances 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008103 glucose Substances 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 150000003626 triacylglycerols Chemical class 0.000 claims 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 230000036772 blood pressure Effects 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 230000001747 exhibiting effect Effects 0.000 claims 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 3
- 201000008980 hyperinsulinism Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000003187 abdominal effect Effects 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- HPXDQBYDTJMQHA-UHFFFAOYSA-N Gedunin Natural products CC1CC2C3(C)C=CC(=O)C(C)(C)C3CC(OC(=O)C)C2(C)C45OC4C(=O)OC(C15)c6cocc6 HPXDQBYDTJMQHA-UHFFFAOYSA-N 0.000 claims 1
- 101150007616 HSP90AB1 gene Proteins 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- WTIJXIZOODAMJT-WBACWINTSA-N [(3r,4s,5r,6s)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2s,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen- Chemical compound O([C@@H]1[C@H](C(O[C@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-WBACWINTSA-N 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- YJXDGWUNRYLINJ-BHAPSIHVSA-N gedunin Chemical compound C=1([C@H]2[C@]3(C)CC[C@@H]4[C@@]5(C)C=CC(=O)C(C)(C)[C@@H]5C[C@H]([C@]4([C@]33O[C@@H]3C(=O)O2)C)OC(=O)C)C=COC=1 YJXDGWUNRYLINJ-BHAPSIHVSA-N 0.000 claims 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims 1
- 229960003538 lonidamine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261652023P | 2012-05-25 | 2012-05-25 | |
| US61/652,023 | 2012-05-25 | ||
| PCT/US2013/042692 WO2013177535A2 (en) | 2012-05-25 | 2013-05-24 | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520170A JP2015520170A (ja) | 2015-07-16 |
| JP2015520170A5 true JP2015520170A5 (enExample) | 2016-07-14 |
| JP6478908B2 JP6478908B2 (ja) | 2019-03-06 |
Family
ID=49624539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514227A Expired - Fee Related JP6478908B2 (ja) | 2012-05-25 | 2013-05-24 | 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9533002B2 (enExample) |
| EP (1) | EP2854865B1 (enExample) |
| JP (1) | JP6478908B2 (enExample) |
| KR (1) | KR20150010793A (enExample) |
| CN (1) | CN104812898B (enExample) |
| AU (1) | AU2013266086B2 (enExample) |
| BR (1) | BR112014029301A2 (enExample) |
| CA (1) | CA2874676A1 (enExample) |
| EA (1) | EA201492184A1 (enExample) |
| HK (1) | HK1209035A1 (enExample) |
| IL (1) | IL235910A0 (enExample) |
| MX (1) | MX2014014188A (enExample) |
| NZ (1) | NZ702169A (enExample) |
| SG (1) | SG11201407775WA (enExample) |
| WO (1) | WO2013177535A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150010793A (ko) * | 2012-05-25 | 2015-01-28 | 버그 엘엘씨 | 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들 |
| EP3434268B1 (en) | 2012-09-27 | 2022-04-20 | The Children's Medical Center Corporation | Compounds for the treatment of obesity and methods of use thereof |
| CN117357538A (zh) * | 2014-03-26 | 2024-01-09 | 儿童医学中心公司 | 用于治疗肥胖症的雷公藤红素和衍生物 |
| AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| CN106687114B (zh) | 2014-06-13 | 2021-08-31 | 尤马治疗公司 | 嘧啶化合物及其使用方法 |
| EP3271005A4 (en) * | 2015-03-19 | 2018-09-05 | Old Dominion University | Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields |
| US10662218B2 (en) * | 2015-10-23 | 2020-05-26 | Erx Pharmaceuticals, Inc. | Analogs of celastrol |
| CN105920018B (zh) * | 2016-06-15 | 2019-01-11 | 上海市内分泌代谢病研究所 | 雷公藤红素联合小檗碱制备治疗肥胖药物的用途 |
| CN107543929A (zh) * | 2016-06-23 | 2018-01-05 | 中国医学科学院肿瘤医院 | 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒 |
| CN107028953A (zh) * | 2017-03-27 | 2017-08-11 | 北京大学 | 一种交感神经活性的刺激剂 |
| EP3615008A4 (en) * | 2017-04-24 | 2021-05-05 | Samus Therapeutics, Inc. | ORAL HSP90 INHIBITOR FORMULATIONS AND RELATED PROCESSES |
| WO2018235251A1 (ja) * | 2017-06-23 | 2018-12-27 | 株式会社ニコン | 解析装置、解析プログラム及び解析方法 |
| CN112156188A (zh) * | 2020-11-10 | 2021-01-01 | 上海交通大学医学院附属瑞金医院 | Hsp90作为制备预防与治疗类固醇糖尿病药物的用途 |
| CN113332308A (zh) * | 2021-02-22 | 2021-09-03 | 广东省妇幼保健院 | 调控hsp90 b1表达量的制剂在制备预防或治疗多囊卵巢综合征药物中的应用 |
| CN113160983A (zh) * | 2021-04-09 | 2021-07-23 | 南京医科大学附属逸夫医院 | 一种代谢相关脂肪性肝病临床预测模型 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078375B1 (en) | 1996-10-25 | 2006-07-18 | Peter Mose Larsen | Diabetes-mediating proteins and therapeutic uses thereof |
| US20040048256A1 (en) | 2001-09-07 | 2004-03-11 | Agee Michele L. | Novel proteins and nucleic acids encoding same |
| JP2006516091A (ja) | 2002-10-07 | 2006-06-22 | アンティジェニクス インコーポレーテッド | 熱ショックタンパク質結合性のｃｄ９１断片およびその使用 |
| US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
| EP1675861B1 (en) | 2003-08-29 | 2015-12-23 | Vernalis (R&D) Ltd. | Pyrimidothiophene compounds |
| WO2005115431A2 (en) | 2004-05-24 | 2005-12-08 | Adonia Papathanassiu | Methods for inhibiting proteasome and heat shock protein 90 |
| CA2574727A1 (en) * | 2004-07-19 | 2006-02-23 | University Of Rochester | Biomarkers of neurodegenerative disease |
| US20060094682A1 (en) | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| WO2007022042A2 (en) | 2005-08-11 | 2007-02-22 | Novartis Ag | Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag |
| US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| WO2007077042A1 (en) | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
| US8658633B2 (en) | 2006-02-16 | 2014-02-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| CA2645930A1 (en) | 2006-03-17 | 2007-09-27 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
| MX2008014437A (es) | 2006-05-19 | 2008-11-27 | Scripps Research Inst | Tratamiento de desplegamiento de proteinas. |
| CA2653222A1 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2661436A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Isoquinoline, quinazoline and phthalazine derivatives |
| US20080070930A1 (en) | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Pyrimidine and Pyrazine Derivatives |
| US20110160175A1 (en) | 2006-09-11 | 2011-06-30 | Christine Martin | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| JP2010516282A (ja) | 2007-01-26 | 2010-05-20 | コーサン バイオサイエンシーズ， インコーポレイテッド | 工学的生合成によるマクロラクタム |
| EA019103B1 (ru) | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| GB2449293A (en) | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| WO2008151833A2 (en) | 2007-06-13 | 2008-12-18 | Hochschule Mannheim | Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds |
| IL184671A0 (en) | 2007-07-17 | 2008-12-29 | Hadasit Med Res Service | Substances directed to heparanase c-terminal domain-or substance derived therefrom and uses thereof as modulators of heparanas biological activities |
| DE102007041116A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | 1,3-Dihydro-isoindolderivate |
| TW200920357A (en) | 2007-09-10 | 2009-05-16 | Curis Inc | HSP90 inhibitors containing a zinc binding moiety |
| EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| WO2009067245A2 (en) | 2007-11-20 | 2009-05-28 | University Of Florida Research Foundation, Inc. | Compositions and methods for tissue repair |
| JP5582783B2 (ja) | 2007-12-28 | 2014-09-03 | 武田薬品工業株式会社 | 細胞保護剤のスクリーニング方法 |
| JP5509100B2 (ja) | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用 |
| WO2009114470A2 (en) | 2008-03-10 | 2009-09-17 | Curis, Inc. | Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety |
| EP2100879A1 (en) | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| KR101446377B1 (ko) | 2008-05-19 | 2014-10-01 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 프리부트 로그인의 지원 방법 및 시스템 |
| JP5767965B2 (ja) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症 |
| US20100022635A1 (en) | 2008-07-28 | 2010-01-28 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
| CN102112481A (zh) | 2008-08-04 | 2011-06-29 | 帝斯曼知识产权资产管理有限公司 | 使用过氧化氢或过酸由鼠尾草酸生产鼠尾草酚的方法 |
| WO2010019965A1 (en) | 2008-08-15 | 2010-02-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection |
| US20110230551A1 (en) | 2008-09-15 | 2011-09-22 | Leslie Gunatilaka | Withaferin a analogs and uses thereof |
| JP2012510442A (ja) | 2008-11-28 | 2012-05-10 | ノバルティス アーゲー | Ｈｓｐ９０阻害剤の組合せ |
| TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
| EP2633884A1 (en) | 2010-01-07 | 2013-09-04 | Akron Molecules GmbH | Obesity small molecules |
| US20110201587A1 (en) | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
| US20120309750A1 (en) | 2010-02-17 | 2012-12-06 | Ildong Pharm Co., Ltd. | 5-membered heterocycle derivatives and manufacturing process thereof |
| CA2697887A1 (en) | 2010-03-12 | 2011-09-12 | Institut De Recherches Cliniques De Montreal | Modulating and/or detecting activation induced deaminase and methods of use thereof |
| US9062072B2 (en) | 2010-04-20 | 2015-06-23 | Emory University | Inhibitors of HIF and angiogenesis |
| CA2825599C (en) | 2011-02-01 | 2021-07-13 | The Board Of Trustees Of The University Of Illinois | 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors |
| US8598339B2 (en) | 2011-02-01 | 2013-12-03 | University Of Kansas | Withanolide isolated from Physalis longifolia and analogs and methods of use thereof |
| WO2012139010A1 (en) | 2011-04-08 | 2012-10-11 | University Of Kansas | Grp94 inhibitors |
| WO2013015661A2 (en) | 2011-07-28 | 2013-01-31 | Ildong Pharm Co.,Ltd. | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
| KR20150010793A (ko) * | 2012-05-25 | 2015-01-28 | 버그 엘엘씨 | 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들 |
| CN102772399A (zh) * | 2012-08-16 | 2012-11-14 | 厦门大学 | 藤黄酸作为5`-amp激活的蛋白激酶激动剂的用途 |
-
2013
- 2013-05-24 KR KR1020147035410A patent/KR20150010793A/ko not_active Withdrawn
- 2013-05-24 AU AU2013266086A patent/AU2013266086B2/en not_active Ceased
- 2013-05-24 JP JP2015514227A patent/JP6478908B2/ja not_active Expired - Fee Related
- 2013-05-24 CA CA2874676A patent/CA2874676A1/en not_active Abandoned
- 2013-05-24 NZ NZ702169A patent/NZ702169A/en not_active IP Right Cessation
- 2013-05-24 CN CN201380039309.5A patent/CN104812898B/zh not_active Expired - Fee Related
- 2013-05-24 HK HK15109711.2A patent/HK1209035A1/xx unknown
- 2013-05-24 SG SG11201407775WA patent/SG11201407775WA/en unknown
- 2013-05-24 BR BR112014029301A patent/BR112014029301A2/pt not_active IP Right Cessation
- 2013-05-24 EA EA201492184A patent/EA201492184A1/ru unknown
- 2013-05-24 US US13/902,354 patent/US9533002B2/en not_active Expired - Fee Related
- 2013-05-24 EP EP13793158.0A patent/EP2854865B1/en active Active
- 2013-05-24 WO PCT/US2013/042692 patent/WO2013177535A2/en not_active Ceased
- 2013-05-24 MX MX2014014188A patent/MX2014014188A/es unknown
-
2014
- 2014-11-25 IL IL235910A patent/IL235910A0/en unknown
-
2016
- 2016-11-21 US US15/357,915 patent/US20170166891A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520170A5 (enExample) | ||
| Kalaki-Jouybari et al. | High-intensity interval training (HIIT) alleviated NAFLD feature via miR-122 induction in liver of high-fat high-fructose diet induced diabetic rats | |
| Bianco-Miotto et al. | Epigenetics and DOHaD: from basics to birth and beyond | |
| DiStefano | Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis | |
| Cirillo et al. | Obesity, insulin resistance, and colorectal cancer: could miRNA dysregulation play a role? | |
| D’Souza et al. | Acute resistance exercise modulates microRNA expression profiles: Combined tissue and circulatory targeted analyses | |
| da Silva et al. | Effects of physical exercise on the expression of MicroRNAs: a systematic review | |
| Liu et al. | Resveratrol attenuates ICAM-1 expression and monocyte adhesiveness to TNF-α-treated endothelial cells: evidence for an anti-inflammatory cascade mediated by the miR-221/222/AMPK/p38/NF-κB pathway | |
| Ling et al. | MicroRNA‐375 promotes 3T3‐L1 adipocyte differentiation through modulation of extracellular signal‐regulated kinase signalling | |
| Qiao et al. | Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features | |
| Evers-van Gogh et al. | Electric pulse stimulation of myotubes as an in vitro exercise model: cell-mediated and non-cell-mediated effects | |
| Satoh et al. | A cellular microRNA, let-7i, is a novel biomarker for clinical outcome in patients with dilated cardiomyopathy | |
| Lou et al. | MicroRNA-142-5p overexpression inhibits cell growth and induces apoptosis by regulating FOXO in hepatocellular carcinoma cells | |
| Guo et al. | Metformin-induced changes of the coding transcriptome and non-coding RNAs in the livers of non-alcoholic fatty liver disease mice | |
| Panico et al. | The influence of lifestyle factors on miRNA expression and signal pathways: a review | |
| Wang et al. | LncRNA-Ang362 promotes pulmonary arterial hypertension by regulating miR-221 and miR-222 | |
| Lundberg et al. | Aerobic exercise augments muscle transcriptome profile of resistance exercise | |
| He et al. | Adenovirus-delivered angiopoietin-1 suppresses NF-κB and p38 MAPK and attenuates inflammatory responses in phosgene-induced acute lung injury | |
| Ogata et al. | Prolonged exercise training induces long-term enhancement of HSP70 expression in rat plantaris muscle | |
| Wang et al. | Inhibition of endoplasmic reticulum stress attenuated ethanol-induced exosomal miR-122 and acute liver injury in mice | |
| Nie et al. | Analysis of non‑alcoholic fatty liver disease microRNA expression spectra in rat liver tissues | |
| Gomes et al. | The implications on clinical diagnostics of using microRNA-based biomarkers in exercise | |
| Khurana et al. | Canvassing the aetiology, prognosis and molecular signatures of obstructive sleep apnoea | |
| He et al. | Circulating miR‐29b positively correlates with non‐alcoholic fatty liver disease in a Chinese population | |
| CN102908621A (zh) | miRNAs作为调节胰岛素敏感性的靶标的新用途 |